Loading...
In December 2023, Walmart CEO Doug McMillon made a startling announcement: customers on GLP-1 drugs were buying measurably less food. Basket sizes were shrinking. The signal was faint but unmistakable — a diabetes drug was rewriting grocery economics. The numbers told a staggering story. By mid-2024, over 6 million Americans had active GLP-1 prescriptions. Novo Nordisk's market cap surged past $570 billion, briefly exceeding Denmark's entire GDP — the company was worth more than the country that housed it. Eli Lilly's stock doubled in 18 months on the strength of Mounjaro and Zepbound. Then the dominoes began falling in unexpected places. Weight Watchers, the 60-year-old dieting empire, saw its stock collapse over 75% as investors concluded that willpower-based programs couldn't compete...
Popular framing: A miracle drug came along and is shaking up the diet industry.
Structural analysis: A single intervention upstream of appetite cascades through every industry whose revenue depends on calorie consumption — snacks, dieting programs, bariatric surgery, even fuel loads — because they were all coupled to the same underlying variable. Second-order effects propagate along the dependency graph faster than incumbents can reposition.
The popular narrative treats disruption as bilateral (drug wins, diet industry loses) because availability cascade dynamics make salient stories feel complete. But the structural reality is that a technology that changes caloric intake at population scale is a slow-moving shock to agricultural, retail, pharmaceutical, and insurance systems simultaneously — most of those second-order effects are invisible until they're irreversible. Understanding the gap matters because premature closure on the 'revolution is done' narrative leads policymakers, investors, and clinicians to optimize for the current disruption while being blindsided by the next wave.
